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Background: Breast cancer is the second leading cause of cancer death after lung
cancer. Discovering molecular biomarkers is necessary for disease management that
includes prognosis prediction and preventive treatment. The aim of this study is to
evaluate the expression value of p53 and PTEN as molecular biomarkers of breast cancer
and their relation with clinicopathological characteristics. 
Methods: In this study, 100 breast cancer and 20 normal samples were subjected
to investigation. Total RNA was isolated and we measured RNA expression by real-
time RT-PCR. Data were analyzed by REST 2009 and SPSS. 
Results: Gene expression results showed up-regulation of P53 in 53 breast cancer
subjects and PTEN in 52 breast cancer subjects compared with normal controls.
However, there was lower P53 expression in 25 breast cancer samples compared to
normal tissues. PTEN expression was lower in 26 breast cancer samples than normal
tissues. p53 showed a significant relationship to HER2 receptor (P=0.024) and
menopausal status (P=0.013); no significant relationships existed with other clinico-
pathological parameters (P>0.05). PTEN had the only significant correlation with
lymphatic invasion (P=0.046) without any relation with other clinicopathological
features (P>0.05).  PTEN expression had no significant association with p53 expression
in the studied population (P=0.074). 
Conclusion: Combined detection of PTEN and p53 may have the potential to
estimate the pathobiological behavior and prognosis of breast cancer. Due to the
heterogeneous nature of cancer and the presence of different factors involved in the
clinical situation of breast cancer, we suggest a study of a larger population and more
biomarkers. 
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Introduction
Although there are numerous advances in
diagnosis and treatment of cancers, they remain
a major problem. Following lung cancer, breast
cancer (BC) is the second leading cause of cancer
death and remains a major health problem.1,2
More than half of BC incidences currently occur
in developed countries, with a rapidly increasing
incidence rate in these geographical areas.3 The
importance of biomarker investigations has been
highlighted in recent years. Disease management,
prognosis, predictive utility, and personalized
medicine are advantages of discovering BC
biomarkers.4 Exploring the correlation of
molecular biomarkers with clinicopathological
parameters can assist with cancer prevention and
management.
Phosphatase and tensin homolog (PTEN) and
TP53 are tumor suppressor genes located on
chromosomes 10q23 and 17p13, respectively.
These proteins are involved in DNA repair,
apoptosis, proliferation, and cell cycle progression.
Therefore, a defect in their functions and changes
in their expressions may result in uncontrollable
tumor cell growth, escape from cell cycle arrest,
and apoptosis signals.5,6
PTEN and p53 are the most frequently mutated
genes in human cancers, particularly primary
BC.6-8 It is reported that mutation followed by
disruption in the regular function of these proteins
leads to angiogenesis, drug resistance, and defects
in apoptosis.7,8 Different studies that discuss
deregulation of p53 in BC have controversial
findings. However, most supported the
overexpression of a mutant p53 and some reported
reduced expression of p53 in BC.10-12 Some
studies reported up-regulated expression of the
biomarker PTEN. In some breast tumors, other
studies reported down-regulation of this
biomarker.14
Correlation of PTEN and p53 expression with
clinicopathological features of BC patients have
been investigated in different areas and different
ethnicities with contradictory results.9-12 In this
study, we aimed to evaluate the mRNA
expressions of p53 and PTEN genes and
investigate the correlation of their expression
signature with clinicopathological parameters in
patients affected with BC.
Materials and Methods
Samples and patients
Breast carcinoma tissues were obtained from
the Cancer Institute of Imam Khomeini Hospital
(Tumor Bank section, Tehran, Iran). Fresh tissues
were divided into two parts: the first slice was
frozen in liquid nitrogen and then preserved at -
80ºC. The second was sent to the Pathology
Laboratory of Imam Hospital for supplementary
investigation. Pathological parameters that
included age, stage, grade, tumor size, lymph
node metastasis, vascular and lymph invasion,
and immunohistochemical situation of ER, PR,
and HER-2 receptors were collected. We
considered 20 normal specimens and 100 tumor
samples diagnosed between 2011 and 2014 for this
study. The Ethics Committee of Tehran University
of Medical Sciences approved this study. All
patients signed an informed consent form prior to
the use of their tissue samples according to the
Declaration of Helsinki (DoH). 
RNA extraction
We extracted the RNA according to previously
reported instructions.13 Briefly, the total RNA
was extracted from 40 mg frozen tissue using
Qiazol reagent according to the supplier’s
instructions (Qiagen, Hilden, Germany). The
tissues were homogenized with a mortar and
pestle. Spectrophotometry was used to determine
the quantity and purity of all extracted RNA for
downstream applications. Next, a 1% agarose gel
electrophoresis was carried out to confirm the
quality and integrity of the RNA samples. RNase
inhibitor (Thermo Fisher Scientific, USA) was
used to prevent RNA degradation. The isolated
RNA were maintained at -80ºC until further use
to avoid degradation.
DNase treatment and cDNA synthesis
DNase reagent was used according to the
manufacturer’s instructions (Thermo Fisher
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Scientific, USA) to prevent genomic DNA
contamination and nonspecific binding. Treated
RNA was then reverse transcribed using random
hexamer primers and a cDNA synthesis kit
according to the manufacturer’s instructions
(Thermo Corporation, Germany). 
Primer design and quantitative expression
examination (qPCR)
The correct reference sequences of each gene
were retrieved from the NCBI nucleotide database
(NCBI GenBank). The appropriate primers were
designed with Primer 3 and Oligo 7 software.
The specificities of all primers were subsequently
checked by performing BLAST. Primers
sequences for PTEN, p53, and GAPDH (reference
internal control) genes were: F: CCAGGACCA-
GAGGAAACCT, R: GCTAGCCTCTGGATT
TGA; F: GTTCCGAGAGCTGAATGAGG, R:
TTATGGCGGGAGGTAGACTG; and F: AAG-
GTCGGAGTCAACGGATTTG, R: GCCAT
GGGTGGAATCATATTGG, respectively. The
lengths of the amplified products were: PTEN
(241 bp), p53 (122 bp), and GAPDH (150 bp). 
Real-time quantitative analysis of gene
expression was performed in a Rotor Gene 2000
Real-Time PCR machine (Qiagen, USA) using the
SYBR Green method (AccuPower Green Star
qPCR Master Mix; Bioneer, Korea) according to
the manufacturer’s instructions.  Each of the gene
expression assays were performed in duplicate 10
µl reactions. PCR cycling was performed as
follows: one cycle at 95ºC for 10 min, 40 cycles
at 95ºC for 20 sec, and 60ºC for 45 sec.  In each
qPCR reaction, an extra melting curve analysis
from 60ºC to 95ºC was run to confirm specific
amplification.  
Pathology
Pathologists from the Pathology Laboratory
(Imam Hospital, Tehran, Iran) assessed all
specimens.  ER, PR, and HER-2 status were
scored by the pathologists by imunohistochemi-
cal examination based on the Hercep test
standards, American Society of Clinical Oncology,
and the College of American Pathologists HER-
2 testing guidelines. Correlation of expression
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Table 1. Correlation of p53 and phosphatase and tensin homolog (PTEN) expression with clinicopathological characteristics.
PTEN expression ( N=78) p53 expression ( N=78)
Low PTEN High PTEN P-value Low p53 High p53 P-value
Number, N (%) 26 (33.3) 52 (66.7) 25 (32.1) 53 (67.9)
Age, 
≤45 (%) 11 (14.5) 14 (18.4) 0.303 6 (7.9) 19 (25) 0.305
˃45 (%) 15 (19.7) 36 (47.4) 19 (25) 32 (42.1)
Tumor size, 
≤5 cm (%) 23 (30.7) 39 (52) 0.523 21 (28) 41 (54.7) 0.531
˃5 cm (%) 3 (4) 10 (13.3) 3 (4) 10 (13.3)
Tumor grade, N (%) 0.203 0.316
I 2 (2.60) 10 (12.80) 4 (5.10) 8 (10.30)
II 15 (19.20) 20 (25.60) 14 (17.90) 35 (44.90)
III 9 (11.50) 22 (28.20) 7 (9) 31 (39.70)
Tumor stage, N (%) 0.372 0.474
I 0 (0) 2 (2.90) 1 (1.40) 1 (1.40)
II 12 (17.10) 29 (41.4) 14 (20.0) 27 (38.60)
III 11 (15.70) 16 (22.90) 6 (8.60) 21 (30.0)
Histology, N (%) 0.559 0.761
Invasive ductal carcinoma 22 (28.9) 39 (51.3) 21 (27.6) 40 (52.6)
Other 4 (5.3) 11 (14.5) 4 (5.3) 11 (14.5)
Metastasis, N (%) 6 (7.7) 13 (16.7) 0.449 3 (3.8) 16 (20.5) 1.000
Lymphatic invasion, N (%) 12 (23.5) 12 (23.5) 0.046 8 (15.7) 16 (31.4) 1.000
Vascular invasion, N (%) 17 (25.8) 21 (31.8) 0.125 10 (15.2) 28 (42.4) 0.431
Necrosis, N (%) 11 (18.6) 17 (28.8) 0.598 10 (16.9) 18 (30.5) 0.572
Lobular carcinoma in situ, N (%) 0 (0) 6 (7.7) 0.845 1(1.3) 5 (6.4) 0.877
Ductal carcinoma in situ, N (%) 16 (21.9) 30 (41) 33 (45.2) 13 (17.8)
Premenopausal, N (%) 15 (20.5) 25 (34.2) 0.623 8 (11) 32 (43.8) 0.013
Postmenopausal, N (%) 10 (13.7) 23 (31.5) 16 (21.9) 17 (23.3)
IHC ER receptor positive, N (%) 18 (23.1) 30 (38.5) 0.459 18 (23.1) 30 (38.5) 0.221
IHC PR receptor positive, N (%) 16 (20.5) 30 (38.5) 0.810 18 (23.1) 28 (35.9)              0.141
IHC Her2 receptor positive, N (%) 6 (7.7) 13 (16.7) 1.000 2 (2.6) 17 (21.8) 0.024
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changes in patients with clinicopathological
features was analyzed.
Statistical analysis
The cycle threshold (CT) values provided by
RT-qPCR were used to calculate the relative fold
expression change according to the 2-ΔΔCT
method. Statistical analysis was carried out via
IBM SPSS Statistics software version 16. The
unpaired t-test and chi-square test were performed
for statistical examination. P-values less than
0.05 were considered statistically significant.
Results
Patients and clinicopathological features
Patients had a mean age of 49.5 years (range:
27-77 years). Based on our examination, more than
half of specimens (51 samples) were lymph node
positive. Table 1 lists a comprehensive overview
of the clinicopathological features in the studied
population.
Expressions of p53 and phosphatase and tensin
homolog (PTEN) in breast cancer (BC) specimens
In this study, we performed quantitative
analyses of the PTEN and p53 gene expressions
by real-time PCR. GAPDH, as the appropriate
housekeeping gene, was used to normalize
expression in the different samples. We excluded
22 out of 100 tumor samples from the study due
to low quality tumor tissue and mRNA. A total of
20 normal tissue samples from the breast margin
were used for relative expression assessment. We
observed that PTEN up-regulated in 52 (66.7%)
and down-regulated in 26 (33.3%) out of a total
of 78 samples. In the TP53 gene, 53 (67.9%)
samples overexpressed, while the remaining 25
(32.1%) had decreased expression. Totally, we
observed significantly different expressions of
PTEN (P=0.002) and p53 (P=0.003) in the BC
specimens compared with normal breast margin
tissues.
Relationship between p53 and phosphatase and
tensin homolog (PTEN) gene expressions and
clinicopathological features of breast cancer (BC)
We compared the gene expression levels of
p53 and PTEN with clinicopathological criteria
according to the chi-square test to determine
significant relations of each parameter with gene
expression. According to table 1, there was only
a significant relation of PTEN gene expression
with lymphatic invasion (P=0.046). Other clini-
copathological characteristics did not show any
significant association with PTEN gene expression
(P>0.05). p53 gene expression did not significantly
correlate with lymph node metastasis, ER receptor
status, PR receptor status, Her2 receptor status,
vascular invasion, age, stage, and tumor grade
(P>0.05). However, p53 expression had a
significant relation to HER-2 receptor status
(P=0.024) and menopausal status (P=0.013). 
Relationship between p53 and phosphatase and
tensin homolog (PTEN) expressions in breast
cancer (BC)
PTEN expression in BC did not show a
significantly positive correlation with p53
expression (P=0.074). Table 2 shows the relation
between the two genes. 
Discussion
Breast cancer is the second most common
cancer worldwide and, by far, the most frequent
cancer among women. Currently, it is the second
cause of cancer death in more developed regions
after lung cancer.1 Discovering molecular
biomarkers with prognostic, predictive, and
diagnostic value is necessary for disease
management.4 p53 and PTEN genes are two
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Table 2. Correlation between expressions of p53 and PTEN in breast cancer (BC).
Correlation between p53 and PTEN gene expression
Up-regulation -p53 Down-regulation-p53 P-value
Up-regulation- PTEN 39 13 0.074
Down-regulation- PTEN 14 12
PTEN: Phosphatase and tensin homolog
PTEN and p53 Expression and Clinicopathological Significance in Breast Cancer
biomarkers that have an important role in BC.14
This study has investigated the expression and
clinicopathological significance of PTEN and
p53 genes in 100 tumor samples (22 out of 100
samples excluded) and 20 normal samples (normal
margin of breast tissue). To our knowledge, most
researches have used immunohistochemistry tests
in pathology laboratories that are based on
antibodies to detect protein molecules.11,15
However, this study used real-time qPCR to detect
the RNA expression status of target genes as a
quantitative method. This method has an
advantage over the IHC (ImmunoHistoChem-
istry) test which is a semi-quantitative method.
Real-time PCR is a highly sensitive, accurate,
reproducible and quantitative method. Hence, it
can be an alternative/complementary method to
determine biomolecular status.16,17 This work had
other advantages that outweigh other studies of the
same subject, which included the simultaneous
assessment of two tumor suppressors and selection
of an appropriate population from Tehran
province, which was representative of different
ethnicities in Iran. According to a number of
studies, different populations and ethnicities show
various expressions of these biomarkers.18
In the current study, we measured the
expressions of PTEN and p53 and compared them
with clinicopathological parameters. Expression
of p53 in BC has been reported to vary from 9%
to 69%. According to our results, the TP53 gene
overexpressed in 67.9% of tumor tissues and
32.1% of tumors had decreased expression.
Therefore, this finding approximately supported
a number of previous studies and slightly
contrasted other studies.9,19,20 RNA expression
of PTEN down-regulated in 33.3% and up-
regulated in 66.7% of tumor tissue samples, which
was similar to other studies.21 It has previously
been reported that loss of PTEN expression occurs
in 30% of sporadic BC and 72% of cases with a
familial history of BC.22 Loss and/or down-
regulation of PTEN and p53 might be related to
loss of heterozygosity or promoter methylation
events. 
As shown in table 1, p53 had a significant
relation to HER-2 receptor (P=0.024) and
menopausal status (P=0.013). This gene did not
have any relation to stage, tumor grade, ER and
PR receptor status, ethnicity, age, tumor size, the
number of positive lymph nodes, lymph node
metastasis, lymphatic invasion, and vascular
invasion (P>0.05). In BC, various tumor
suppressors, including p53, are mutated. Mutations
in this gene are associated with tumor growth,
increased angiogenesis, dysfunction of apoptosis,
and chemotherapy treatment resistance.23,24
Studies in other countries have shown that the
expression of the p53 gene in BC can also be
considered an important factor in disease
prognosis.25 Information about p53 status in
certain cancers may be helpful in disease
management of the diagnosis, therapeutic
decisions, and prognosis prediction.26 Previous
literatures have demonstrated that p53 expression
has a significant positive correlation with high
proliferation index (MIB1), increased grade
values, a negative correlation with steroid receptor
status, and a significant association with lower age,
larger tumor size, ductal morphology, and high
tumor grade.27 Patients’ survival and response to
therapy have been reportedly predicted based on
knowledge of the p53 mutation status.28 In one
study, expressions of PTEN and PIK3CA in tumor
tissue significantly increased compared to normal
tissue. Expressions of PTEN and PIK3CA in
tumor tissue showed no correlations with
metastasis in the lymph nodes.29
According to table 1, a significant relation
existed between lymphatic invasion (P=0.046)
and the PTEN gene. We did not observe any
correlations with other clinicopathological factors
(P>0.05). The PI3K/PTEN pathway plays a vital
role in carcinogenesis. This pathway controls
multiple important cellular functions such as
metabolism, cell proliferation, apoptosis,
migration, and survival. Inappropriate regulation
of this route often occurs in BC and the lack of
PTEN expression has been suggested as a major
mechanism for resistance against HER-2
treatment.30,31 Rapid metastasis of some tumors
has been found to be associated with mutations in
Middle East J Cancer 2018; 9(2): 105-111 109
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p53 and PTEN.32 Although some studies indicated
no correlations between PTEN and clinicopatho-
logical parameters, other reports showed an
association between loss of PTEN expression and
high tumor grade, presence of lymphatic invasion,
and a high proliferative index (22, 33).27,36
Furthermore, it has been reported that ER+ status,
small tumor size, and low HER-2 expression
correlated with loss of PTEN.34 This discrepancy
among different literatures probably resulted from
the small sample size, different ethnicities, and
genetic heterogeneity.
PTEN and p53 are two tumor suppressor genes
most commonly related to various cancers. It has
been indicated that PTEN and p53 are functionally
related through the PI3K signaling pathway.5
PTEN also affects cellular functions independently
of the PI3K pathway via direct binding to p53 and
prevention of its degradation.35 Although PTEN
and p53 are not the only mechanisms to suppress
tumor progression in cancer, their co-expression
status could have significance in disease
management. Our results have revealed that
expression status of PTEN and p53 did not
significantly correlate (P=0.074). We did not
investigate gene mutations in PTEN and p53 in the
present study and false-negative or false-positive
findings might be other limitations. 
In conclusion, the results of this study had
some consistencies and inconsistencies with
previous literatures due to genetic heterogeneity
of BC between different geographical regions,
differences in ethnicities, and the variety of sample
size. The expression status of PTEN showed a
significant correlation with lymphatic invasion,
while p53 had a significant association with
menopausal and HER-2 receptor status.
Assessments of PTEN and p53 expressions might
provide information helpful to the management of
BC, regardless of the underlying mechanisms
that drive gene expression alterations in cancer
cells.
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